Cladribine Venetoclax in Monocytic AML - Trial NCT06232655
Access comprehensive clinical trial information for NCT06232655 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Colorado, Denver and is currently Not yet recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Colorado, Denver
Timeline & Enrollment
Phase 2
Dec 01, 2024
Oct 01, 2027
Primary Outcome
Overall response rate (ORR)
Summary
Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of
 hypomethylating agent+venetoclax
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06232655
Non-Device Trial